The Rheumatoid Arthritis (RA) treatment paradigm continues to evolve as new therapeutic options are added to physicians’ toolkits. The positioning of newer agents (, Pfizer’s Xeljanz, Janssen’s Simponi Aria) in the treatment algorithm is still being established in some cases, and has reached a relative steady state in others. ChartTrends®: Rheumatoid Arthritis (US) 2014 explores the current status quo in RA treatment based on both physician reports and actual practice through the use of patient chart data.
Questions Answered in This Report:
- Amgen’s Enbrel, AbbVie’s Humira, and Janssen’s Remicade are the patient-share market leaders, according to physician reports. How has the recent launch of Xeljanz, a new oral disease-modifying antirheumatic drug (DMARD) impacted the shares of biological agents? How has the availability of new formulations—Simponi Aria intravenous (IV) and Roche’s Actemra subcutaneous (SC) formulations—impacted the overall use of the brand?
- The patient factors driving the treatment decision for RA are multifaceted and complex. How does a Xeljanz user differ demographically from an Enbrel user, for example?
- The majority of RA patients receive a radiographic testing at initiation of a biologic or Xeljanz. What is the current standard of care in RA diagnosis and disease tracking? What tests are being used and does this differ for the different treatment options?
Markets covered: United States.
Primary research: 212 surveyed rheumatologists; 1, 003 RA patient records.